Search Results

There are 3706 results for: content related to: Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells

  1. Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam

    The Journal of Clinical Pharmacology

    Volume 55, Issue 4, April 2015, Pages: 401–408, Hefei Zhang, Jennifer Sheng, Jin H. Ko, Cheng Zheng, Wei Zhou, Petra Priess, Wen Lin and Steven Novick

    Version of Record online : 27 FEB 2015, DOI: 10.1002/jcph.434

  2. Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: An insight

    Clinical and Experimental Pharmacology and Physiology

    Volume 41, Issue 10, October 2014, Pages: 788–797, Gamal E Shiha, Nashwa M Abu-Elsaad, Khaled R Zalata and Tarek M Ibrahim

    Version of Record online : 30 OCT 2014, DOI: 10.1111/1440-1681.12286

  3. You have full text access to this Open Access content
    Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

    Journal of Cellular and Molecular Medicine

    Volume 12, Issue 5b, October 2008, Pages: 2107–2118, J. Chen, A. Schmitt, B. Chen, M. Rojewski, V. RuBeler, F. Fei, Y. Yu, X. Yu, M. Ringhoffer, S. von Harsdorf, J. Greiner, M. Gbtzz, P. Guillaume, H. Dbhner, D. Bunjes and M. Schmitt

    Version of Record online : 11 JAN 2008, DOI: 10.1111/j.1582-4934.2008.00234.x

  4. Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 51, Issue 1, January 2011, Pages: 75–83, Dr Chiaki Tanaka, Dr Ophelia Q. P. Yin, Dr Tom Smith, Dr Venkat Sethuraman, Ms Karen Grouss, Dr Lawrence Galitz, Dr Robert Harrell and Dr Horst Schran

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270010367428

  5. Effects of Yogurt and Applesauce on the Oral Bioavailability of Nilotinib in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 51, Issue 11, November 2011, Pages: 1580–1586, Dr Ophelia Q. P. Yin, Dr Marc Rudoltz, Dr Ivana Galetic, Dr Jeiry Filian, Dr Arun Krishna, Dr Wei Zhou, Dr Joseph Custodio, Dr Georg Golor and Dr Horst Schran

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010384116

  6. Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib—a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer

    The Journal of Clinical Pharmacology

    Volume 54, Issue 11, November 2014, Pages: 1272–1279, Venkateswaran C. Pillai, Robert A. Parise, Susan M. Christner, Michelle A. Rudek, Jan H. Beumer and Raman Venkataramanan

    Version of Record online : 27 MAY 2014, DOI: 10.1002/jcph.333

  7. Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 50, Issue 2, February 2010, Pages: 188–194, Dr Ophelia Q. P. Yin, Dr Neil Gallagher, Dr Ai Li, Dr Wei Zhou, Dr Robert Harrell and Dr Horst Schran

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009336137

  8. Effect of the Proton Pump Inhibitor Esomeprazole on the Oral Absorption and Pharmacokinetics of Nilotinib

    The Journal of Clinical Pharmacology

    Volume 50, Issue 8, August 2010, Pages: 960–967, Dr Ophelia Q. P. Yin, Dr Neil Gallagher, Dr Deirdre Fischer, Dr Eren Demirhan, Dr Wei Zhou, Dr Georg Golor and Dr Horst Schran

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009346061

  9. Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

    Clinical Pharmacology & Therapeutics

    Volume 87, Issue 2, February 2010, Pages: 197–203, C Tanaka, O Q P Yin, V Sethuraman, T Smith, X Wang, K Grouss, H Kantarjian, F Giles, O G Ottmann, L Galitz and H Schran

    Version of Record online : 18 NOV 2009, DOI: 10.1038/clpt.2009.208

  10. Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability

    Biopharmaceutics & Drug Disposition

    Volume 33, Issue 9, December 2012, Pages: 536–549, Binfeng Xia, Tycho Heimbach, Handan He and Tsu-han Lin

    Version of Record online : 19 NOV 2012, DOI: 10.1002/bdd.1821

  11. Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 3, March 2014, Pages: 294–306, L N Eadie, T P Hughes and D L White

    Version of Record online : 9 OCT 2013, DOI: 10.1038/clpt.2013.208

  12. Are nilotinib-associated vascular adverse events an under-estimated problem?

    Fundamental & Clinical Pharmacology

    Volume 29, Issue 2, April 2015, Pages: 204–208, Marie Stève-Dumont, Bernadette Baldin, Laurence Legros, Antoine Thyss, Daniel Re, Fanny Rocher, Florian Ajmia, Anne Spreux and Milou-Daniel Drici

    Version of Record online : 11 MAR 2015, DOI: 10.1111/fcp.12102

  13. You have free access to this content
    Nilotinib Interferes with the Signalling Pathways Implicated in Acetaminophen Hepatotoxicity

    Basic & Clinical Pharmacology & Toxicology

    Volume 114, Issue 3, March 2014, Pages: 263–270, Mohamed E. Shaker

    Version of Record online : 23 OCT 2013, DOI: 10.1111/bcpt.12144

  14. You have free access to this content
    Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

    Cancer

    Volume 121, Issue 6, March 15, 2015, Pages: 863–871, Avichai Shimoni, Yulia Volchek, Maya Koren-Michowitz, Nira Varda-Bloom, Raz Somech, Noga Shem-Tov, Ronit Yerushalmi and Arnon Nagler

    Version of Record online : 11 NOV 2014, DOI: 10.1002/cncr.29141

  15. You have free access to this content
    Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

    Cancer

    Volume 118, Issue 21, 1 November 2012, Pages: 5265–5269, Marzia Defina, Micaela Ippoliti, Alessandro Gozzetti, Elisabetta Abruzzese, Fausto Castagnetti, Rosaria Crupi, Mario Tiribelli, Massimo Breccia, Marzia Salvucci, Lara Aprile, Claudia Baratè, Antonella Gozzini, Gianantonio Rosti, Francesco Lauria and Monica Bocchia

    Version of Record online : 19 APR 2012, DOI: 10.1002/cncr.27506

  16. You have free access to this content
    Practical management of patients with chronic myeloid leukemia

    Cancer

    Volume 117, Issue 19, 1 October 2011, Pages: 4343–4354, Francisco Cervantes and Michael Mauro

    Version of Record online : 16 MAR 2011, DOI: 10.1002/cncr.26062

  17. Treatment-, Patient-, and Disease-Related Factors and the Emergence of Adverse Events with Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 33, Issue 8, August 2013, Pages: 868–881, Elizabeth Irvine and Casey Williams

    Version of Record online : 3 APR 2013, DOI: 10.1002/phar.1266

  18. Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling

    Journal of Pharmacy and Pharmacology

    Christel C.L.M. Boons, Abdel Chahbouni, Anneliene M. Schimmel, Abraham J. Wilhelm, Yvonne M. den Hartog, Jeroen J.W.M. Janssen, N. Harry Hendrikse, Jacqueline G. Hugtenburg and Eleonora L. Swart

    Version of Record online : 23 JUN 2017, DOI: 10.1111/jphp.12757

  19. You have free access to this content
    Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

    American Journal of Hematology

    Volume 86, Issue 7, July 2011, Pages: 533–539, Karl J. Aichberger, Susanne Herndlhofer, Gerit-Holger Schernthaner, Martin Schillinger, Gerlinde Mitterbauer-Hohendanner, Christian Sillaber and Peter Valent

    Version of Record online : 27 APR 2011, DOI: 10.1002/ajh.22037

  20. You have full text access to this OnlineOpen article
    Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd

    British Journal of Haematology

    Timothy P. Hughes, Eduardo Munhoz, Marco Aurelio Salvino, Tee Chuan Ong, Alaa Elhaddad, Jake Shortt, Hang Quach, Carolina Pavlovsky, Vernon J. Louw, Lee-Yung Shih, Anna G. Turkina, Luis Meillon, Yu Jin, Sandip Acharya, Darshan Dalal and Jeffrey H. Lipton

    Version of Record online : 12 JUL 2017, DOI: 10.1111/bjh.14829